<!DOCTYPE html>

<html lang="en">
<head>
<meta charset="utf-8"/>
<title>article2</title>
<style>
        body {
            font-family: Arial, sans-serif;
            margin: 0;
            padding: 0;
            background-color: #f3f3f3;
        }
        .container {
            max-width: 800px;
            margin: auto;
            background: #fff;
            padding: 20px;
            box-shadow: 0 0 10px rgba(0, 0, 0, 0.1);
        }
        h1, h2 {
            color: #333;
        }
        p {
            line-height: 1.6;
        }
        a {
            text-decoration: none;
            color: #5a5a5a;
        }
        a:hover {
            color: #000;
        }
    </style>
</head>
<body>
<div class="container"><p><a href="../index_gpt.html">Back to Index</a></p><li><a href="https://www.wikijournalclub.org/wiki/CHAMPION_PHOENIX" style="display:block; margin-bottom:10px;">CHAMPION PHOENIX Original</a></li>
<h2><strong>CHAMPION PHOENIX</strong></h2>
<div class="container">
<h2><strong></strong></h2>
<div class="container">
<div class="container">
<h2><strong></strong></h2>
<h2><strong></strong></h2>

    "Cangrelor During PCI".The New England Journal of Medicine. 2013. 368:1303-1313.PubMed•Full text•PDF<br/>
<br/>
<h2><strong>Contents</strong></h2><br/>
1 Clinical Question<br/>
2 Bottom Line<br/>
3 Major Points<br/>
4 Guidelines<br/>
5 Design<br/>
6 Population<br/>
6.1 Inclusion Criteria<br/>
6.2 Exclusion Criteria<br/>
6.3 Baseline Characteristics<br/>
7 Interventions<br/>
8 Outcomes<br/>
8.1 Primary Outcome<br/>
8.2 Secondary Outcomes<br/>
9 Criticisms<br/>
10 Funding<br/>
11 Further Reading<br/>
<br/>
<h2><strong>Clinical Question</strong></h2><br/>
In patients undergoing PCI and receiving guideline-recommended therapy, does cangrelor compared to clopidogrel reduce periprocedural ischemic complications without increasing the risk of severe bleeding?<br/>
<br/>
<h2><strong>Bottom Line</strong></h2><br/>
In patients undergoing PCI, cangrelor reduced ischemic events, including stent thrombosis during PCI, with no significant increase in severe bleeding compared to clopidogrel.<br/>
<br/>
<h2><strong>Major Points</strong></h2><br/><br/>
<br/>
<h2><strong>Guidelines</strong></h2><br/>
The role of cangrelor during PCI has not been fully reflected in current guidelines.<br/>
<br/>
<h2><strong>Design</strong></h2><br/>
- Multicenter, double-blind, placebo-controlled trial.<br/>
- N=11,145 patients undergoing urgent or elective PCI.<br/>
- Cangrelor + clopidogrel placebo (n=5,571).<br/>
- Clopidogrel + cangrelor placebo (n=5,574).<br/>
- Setting: 153 sites globally.<br/>
- Enrollment: September 30, 2010, to October 3, 2012.<br/>
- Primary efficacy outcome: Composite of death, myocardial infarction, ischemia-driven revascularization, or stent thrombosis at 48 hours.<br/>
- Primary safety outcome: Severe bleeding at 48 hours.<br/>
<br/>
<h2><strong>Population</strong></h2><br/>
Inclusion Criteria<br/>
- Coronary atherosclerosis requiring PCI for stable angina, non–ST-segment elevation acute coronary syndrome, or STEMI<br/>
- Not received pretreatment with platelet inhibitors<br/>
<br/>
Exclusion Criteria<br/>
- Receipt of P2Y12 inhibitor or abciximab within 7 days before randomization<br/>
- Receipt of eptifibatide or tirofiban or fibrinolytic therapy within 12 hours before randomization.<br/>
<br/>
Baseline Characteristics<br/>
- Mean age 64 years.<br/>
- 28% were female.<br/>
- 56.1% stable angina, 25.7% non–ST-segment elevation acute coronary syndrome, 18.2% STEMI.<br/>
<br/>
<h2><strong>Interventions</strong></h2><br/>
- Cangrelor was administered as a bolus followed by an infusion for at least 2 hours or the duration of the procedure, whichever was longer.<br/>
- Clopidogrel loading dose determined by site investigator (600 mg or 300 mg).<br/>
<br/>
<h2><strong>Outcomes</strong></h2><br/>
Primary Outcome<br/>
- Rate of primary composite efficacy end point at 48 hours was 4.7% in the cangrelor group vs. 5.9% in the clopidogrel group (adjusted odds ratio 0.78; P=0.005).<br/>
<br/>
Secondary Outcomes<br/>
- Stent thrombosis developed in 0.8% in the cangrelor group and 1.4% in the clopidogrel group (odds ratio, 0.62; P=0.01).<br/>
<br/>
<h2><strong>Criticisms</strong></h2><br/>
- The role of cangrelor in patients pretreated with oral P2Y12 inhibitors or those who require transition to prasugrel or ticagrelor was not assessed in this trial.<br/>
- A further study is needed to determine the most effective way to transition from cangrelor to other P2Y12 inhibitors.<br/>
<br/>
<h2><strong>Funding</strong></h2><br/>
Supported and designed by the Medicines Company.<br/>
<br/>
<h2><strong>Further Reading</strong></h2><br/>
Original publication at NEJM.org.
    <p></p>
</div>
</div>
</div>
</div>
</body>
</html>
